Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee.

Trial Profile

Intra-articular and Intravenous Infliximab in the Treatment of Resistant Seronegative Oligoarthritis of the Knee.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 May 2016

At a glance

  • Drugs Infliximab; Infliximab; Methylprednisolone
  • Indications Arthritis
  • Focus Therapeutic Use
  • Acronyms SOKS
  • Most Recent Events

    • 10 May 2016 Status changed from recruiting to discontinued as were unable to recruit participants.
    • 13 Oct 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top